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Summary Expression of the bcl-2 gene was investigated in 218 human breast carcinomas by immunohistochemical analysis.
Immunodetections were assessed using (1) frozen sections, (2) documented commercially available monoclonal antibody (bcl-2/124, Dako),
(3) automation of immunoperoxidase technique (Ventana) and (4) quantitative evaluation of results by imageanalysis (SAMBA) and statistical
analysis of quantitative data (BMDP software). Bcl-2 protein expression was correlated with current prognostic indicators and with molecular
markers detected bythe same procedure as for Bcl-2. It was shown that Bcl-2 expression is not related to patients' age, tumoursize and type
or lymph node status, but an inverse relationship was observed between Bcl-2 and tumour grade (P < 0.0001). An inverse relationship
was also observed between Bcl-2 expression and p53 (P<0.0001), Ki67/MIB1 antigen- (P=0.0012), and P-gp- (P=0.002) positive
immunoreactions. In contrast, anti-Bcl-2 positive reaction was significantly associated with ER-positive (P < 0.001) and with ER/PR-positive
or ER/PR/pS2-positive immunoreactions (P < 0.005). Bcl-2 expression was independent of CD31 and cathepsin D expression. Thus, Bcl-2
protein, thought to be antiapoptotic, exhibits parodoxical expression in human breast carcinomas. It is strongly detected in low-grade tumours
(well-differentiated) with low (MIB13) growth fraction, but is independent ofthe tumour progression (size, node status, CD31, andcathepsin D).
Bcl-2 acting on apoptosis is related to p53 gene abnormalities in breast carcinomas. Bcl-2 protein expression may also be involved in
response to endocrine therapy (associated to ER/PR/pS2 positive immunoreactions) and probably with chemoresistance mechanisms
(inverse relationship with P-gp).
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Bcl-2 gene abnormality was first reported in non-Hodgkin's
lymphomas (Tsujimoto et al, 1985), in which t(14;18) chromo-
somal translocation results in an inappropriately high level ofbel-
2 gene expression (Korsmeyer, 1992). The protein encodedby this
gene has been shown to contribute to malignant cell expansion by
prolonging cell survival (Vaux et al, 1988) and delaying or
blocking programmed cell death/apoptosis (Hockenbery et al,
1990; Siegel et al, 1992). The human Bcl-2 protein is an intra-
cellular membrane protein with a molecular mass of 24 kDa
(Chen-Levy et al, 1989, 1990). It resides in the nuclear envelope,
endoplasmic reticulum and outer mitochondrial membranes
(Krajewski et al, 1993) with a non-uniform distribution suggestive
ofparticipation in protein complexes (Krajewski et al, 1993).
Apoptosis is an active form of cell death (Wyllie et al, 1987),
requiring activation of endonucleases inducing the degradation of
nuclear DNA of the cell into oligonucleosome-length fragments.
Apoptosis plays an important role in normal physiological condi-
tions, but in proliferative cells andtumours itmay alsobethe target
for chemotherapeutic drugs that can kill cancer cells by activating
biochemical pathways leading to programmed cell death (Eastman
et al, 1990). Drugs may act on the apoptotic process by inhibition
of antiapoptotic factors up-regulated in malignant tumours.
Chemoresistance may result from antiapoptotic protection from
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cell death and DNA fragmentation inducedby antineoplastic drugs
(Miyashita, 1992, 1993). In this regard high levels ofBcl-2 protein
have been shown to protect lymphoid cells from antineoplastic
drugs (Miyashita, 1992, 1993). In leukaemic cells, it can inhibit
apoptosis induced by glucocorticoids (Alnemri et al, 1992) and 5-
fluorodeoxyuridine or taxol (Fisher et al, 1993). Thus, detection of
this protein in tissue may beinformative formonitoring the therapy
of patients with cancer. However, the true significance of Bcl-2
protein expression in tumours still remains to be investigated
accurately, particularly in human breast carcinomas.
In breast carcinomas a high fraction of Bcl-2-positive cells
correlates with good prognostic indicators (Silvestrini et al, 1994),
longer survival in node-positive patients (Hellemans et al, 1995),
and oestrogen receptor status (ER) (Alnemri et al, 1992; Johnston
et al, 1994; Silvestrini et al, 1994; Hellemans et al, 1995; Baba et
al, 1996). In addition, a highly significant relationship has been
observed between the response to endocrine therapy and the pres-
ence ofBcl-2protein in the tumour(Gee etal, 1994). Bcl-2protein
expression has been shown to be enhanced in ER-positive tumours
after tamoxifen in association with reduced cell proliferation
(Johnston et al, 1994). These results in breast carcinomas are
somewhat paradoxical as it would be expected that Bcl-2 protein
would counteract the tumour-inhibitory effect of endocrine
therapy and that it would be down-regulated in tumours with good
prognosis, with an inverse relationship with survival rates, as it is
thought to prevent programmed cell death.
Only a few recent studies screening Bcl-2 protein expression in
breast carcinomas have been reported (Silvestrini et al, 1994;
Hellemans et al, 1995; Johnston et al, 1994; Baba et al, 1996), and
in these reports methods of investigation were different. When
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immunohistochemistry was used to detect Bcl-2 protein in tissue
sections from the tumours, samples were either fixed and paraffin
embedded (Johnston et al, 1994; Silvestrini et al, 1994; Hellemans
etal, 1995; Baba etal, 1996) orfrozen (Gee etal, 1994). Antibodies
directed against Bcl-2 protein were also different and variably
diluted. Results were evaluated by semiquantitative analysis, which
relies on the observers' subjectivity, with variable and arbitrary
'cut-off' points (Johnston et al, 1994; Hellemans et al, 1995). The
rates of Bcl-2 protein-positive tumours were highly variable,
ranging from 32% to 75% (Gee et al, 1994; Johnston et al, 1994;
Silvestrini et al, 1994; Hellemans et al, 1995; Baba et al, 1996). As
already mentioned (Johnston et al, 1994), validation of statistical
analysis is difficult because of the lack of standardization of
immunohistochemical assays and therefore practical conclusions,
particularly with regard to the clinical significance ofBcl-2 expres-
sion in tissue, may not be clearly drawn from the literature survey.
In the present study, we have evaluated Bcl-2 protein expression
in 218 breast carcinomas using immunohistochemical assays
assessed in optimal technical conditions. Bcl-2 expression was
detected (1) on frozen sections (with no risk of antigen damage
owing to fixation and heating during paraffin embedding), (2)
using a well-documented commercially available antibody
(Dako/Bcl-2, 124), (3) by automated immunodetection (Ventana
device) more reproducible than manual procedures and (4) by
quantitative analysis of the results by densitometry of digitized
coloured microscopic images (image analyser SAMBA). Bcl-2
expression in tumours was correlated with histological prognostic
indicators and with expression of proteins also endowed with
prognostic significance, such as growth fraction (detected by
MIB1), pS3, CD-31 (angiogenesis), cathepsin D (extracellular
matrix protease) and hormone receptors and P-gp (multidrug
resistance) evaluated according to the same procedure.
MATERIAL AND METHODS
Source of tissue samples
The specimens were surgically obtained from 218 patients with
breast carcinomas from January 1993 to May 1994. Mean age was
56.7 years (range 32-83 years). For all patients surgical resection
was the primary treatment and none received irradiation or
chemotherapy preoperatively. Surgical specimens were fixed in
Bouin's fixative, paraffin embedded and stained with haema-
toxylin, eosin and saffronin for routine microscopic diagnosis.
Samples for immunodetection were taken, by pathologists, from
the representative cancerous lesions, in the same area as the
sample used for the intraoperative microscopic diagnostic assessed
on frozen sections. Tissue samples for immunodetections were
promptly dipped in liquid nitrogen and stored frozen at -80°C in
the tumour library ofour laboratory.
Histopathological features
Tumour size ranged from 4 to 80 mm (mean = 16.8, s.d. = 11.95,
median = 15 mm). In 90% of patients (198/218), axillary lymph
node excision was performed; 62% (n = 124) were node negative
and 38% (n = 75) were node positive.
Tumours were in situ in 17/218 cases (8%). Invasive ductal
carcinomas accounted for 66% of cases (143/218), lobular carci-
nomas for 17% (38/218) and invasive carcinomas of other types
for 9% (20/218).
Tumours were graded according to the Bloom grading system
(SBR) (Bloom, 1957). Grade I tumours accounted for 22%
(45/201), grade II tumours for 54% (108/201) and grade III
tumours for24% (48/201). Tumours were also graded according to
a modified Bloom grading system (Le Doussal et al, 1989) into
five grades: 8% ofgrade I, 30% ofgrade II, 31% ofgrade III, 27%
of grade IV and 4% of grade V. Tumours were also ranked
according to the Nottingham prognostic index (NPI) (Galea et al,
1992), which ranged from 2.1 to 7.3 (mean = 4.1, s.d. = 1.22).
Immunohistological staining procedures
Antibodies sources
Monoclonal mouse anti-human Bcl-2 oncoprotein (Dako, bcl-2/
124, diluted 1: 100) recognizes a peptide sequence comprising
amino acids 41-54 ofBcl-2 protein (Clearly et al, 1986; Tsujimoto,
1986). The other monoclonal antibodies used were all commer-
cially available and used as described previously (Charpin et al,
1988 a-c; 1993, 1994, 1995a, b; Charpin and Pellissier, 1994):
MIB1 and anti-CD-31 (Immunotech, Marseille, France), anti-p53
clone DO-6 (Oncogene Science, Paris, France), anti-cathepsin D
(CisBio International, Gif sur Yvette, France), anti-P-glycoprotein
(P-gp) clone JSB1-N (Tebu, Le Perray en Yvelines, France), anti-
oestrogen and progesterone receptors (ER/PR) (Abbott kits,
Rungis, France).
Automated immunohistochemistry
Automated immunohistochemisty (immunoperoxidase) was
performed on consecutive sections (4 gm thick) on Ventana 320
device (Grogan et al, 1993; 1995; Galaktionov et al, 1995)
(Ventana Medical Systems, Tucson, AZ, USA) with Ventana kits
(Ventana Medical Systems, Strasbourg, France) including also
amino-ethyl carbazol reagent. Sections were counterstained with
haematoxylin, dehydrated and mounted in glycergel.
Image processing and statistical analysis
Immunostaining was analysed using an Axiophot microscope
(Zeiss, Rueil Malmaison, France) and a 3 CCD camera (Sony,
Figure 1 Immunohistochemical procedure using frozen sections, anti-Bcl-2
and 124 (Dako, 1:100) avidin-biotin-peroxidase (automated procedure/
Ventana). In invasive ductal carcinoma, the distribution of Bcl-2 protein is
heterogeneous, involving not all the tumour cells and partly involving the
cytoplasm adjacent to the cell membrane
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Figure 2 Immunohistochemical procedure using frozen sections, anti-Bcl-2
and 124 (Dako, 1:100) avidin-biotin-peroxidase (automated procedure/
Ventana). High magnification shows that Bcl-2 protein is located in the cell,
focally along cell membrane cytoplasm, and along nuclei (invasive lobular
carcinoma)
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Paris, France) and then processed by an image analysis system
(SAMBA 2005, Alcatel-TITN, Grenoble, France) (Brugal et al,
1979). The two parameters of densitometric analysis, percentage
of immunostained surface (vs counterstained surface) and mean
optical density (MOD), which reflects the staining intensity
(SAMBA arbitrary units scale ranging from 0 to 255), were
obtained as previously reported (Charpin et al, 1988 a-c, 1994,
1995; Charpin and Pellissier, 1994). Statistical analysis was
assessed using BMDP (Biomedical Data Package) software
(University of California, Berkeley, CA, USA). Various statistical
tests were used, depending upon the type (nominal or ordinal) and
the distribution (normal or not) of the variables. Consequently,
parametric or non-parametric tests were applied, including the chi-
square test, Student's t-test, Kruskal-Wallis test, Mann-Whitney
U-test, and the computation ofcorrelation coefficients (Spearman,
Kendall and Pearson). In addition, a quantitative index of
immunoreactions (QIC) (Maudelonde et al, 1993), combining the
percentage of stained surface and mean optical density (MOD),
was computed (per cent of stained surface/MOD x 100).
RESULTS
Bcl-2 distribution patterns in cells and tissues
Patterns of immunoreaction are shown and described in detail in
Figures 1 and 2. In brief, anti-Bcl-2/124 reacted only with epithe-
lial tumour cells and not with lymphocytes or with stromal cells.
The positive immunoreactions with anti-Bcl-2 did not differ in
ductal carcinomas, lobular carcinomas or carcinomas of other types
and was observed in cellcytoplasm focally along the cell membrane.
In intraductal carcinomas or in intraductal component ofinvasive
carcinomas the positive Bcl-2 immunostaining exhibited the same
pattern as seen in invasive areas. In normal breast present along
tumourborders, apositive Bcl-2 reaction was focally observed.
Bcl-2 quantitative immunodetection
Among the 218 tumours probed, 171 (78%) were Bcl-2 positive
and 47 were Bcl-2 negative. Distribution of anti-Bcl-2 positive
staining evaluated by densitometry on tissue sections is shown on
Figure 3A and B. Inpositive tumours the tumour surface stained by
anti-Bcl-2 ranged from 3% to 70% (mean = 22.4%, s.d. = 12.1)
(Figure 3A). The Bcl-2 quantitative immunocytochemical index
(QIC) varied from 2.6 to 49.2 (mean = 15.2, s.d. = 9.8) (Figure 3B).
Bcl-2 expression and clinicopathological data
Bcl-2-immunostained surface evaluated by image analysis and
QIC was independent of the patients' age, the tumour size, the
histological type, lymph node status and the NPI.
In contrast, an inverse relationship was observed between Bcl-2
expression and tumour grades (Table 1), with a significant
___________________ (P < 0.001) decrease in Bcl-2 expression in high-grade tumours,
30 40 50 suggesting that Bcl-2 protein is down-regulated in poorly differen-
tiated tumours.
Figure 3 Immunohistochemical procedure using frozen sections, anti-Bcl-2
and 124 (Dako, 1:100) avidin-biotin-peroxidase (automated procedure/
Ventana), and quantitative image analysis (SAMBA). (A) Distribution of Bcl-2
immunostained surface (per cent of positive surface/counterstained surface).
(B) Distribution of quantitative immunocytochemical index (per cent of
stained surface/mean optimal density x 100) in the series investigated
(n = 218 breast carcinomas)
Bcl-2 expression and quantitative immunodetection of
other molecular markers
Results of quantitative evaluation of anti-ER and PR antigenic
sites and anti-pS2, of growth fraction (MIB1), and also of
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Table 1 Correlation of Bcl-2 expression and tumour grades (218 breast carcinomas)
Tumour grades Bcl-2 immunohistochemical expression
Bcl-2 negative Bcl-2 positive
(n = 43) (% stained surface)
Grade (Bloom)
1 5 (12%) 27.4% ± 11.5
2 13 (30%) P < 0.001a 22.3% ± 9.3 P= 0.011b
3 25 (58%) 5.8% ± 7.2
Grade modified (Le Doussal)
1 + 2 (group 1) 8 (18%) 24.7% ± 10.5
3 (group 11) 10 (23%) P< 0.001a 20.5% ± 8.4 P= 0.0043b
4+5 (group 111) 25 (59%) 14.3% ± 5.4
aChi-square. bKruskal-Wallis.
Table 2 Correlation of Bcl-2 protein (anti bcl-2/124, Dako) and oestrogen and progesterone receptorantigenic sites (ER, PR) and
P-S2 detected by automated (Ventana) and quantitative (SAMBA) immunohistochemistry in 218 breast carcinomas.
Bcl-2 immunoreaction
Positive surface (%) alGa
ER
Positive 24 (±10) 16 (±10)
pb = 0.004 pb =0.005
Negative 14 (±8) 11 (±6)
ER/PR
Positive 25 (±13) 19 (±12)
pb = 0.005 Pb 0.0018
Negative 11 (±9) 12 (±10)
ER/PR/pS2
Positive 24 (±16)
pb = 0.001 NSb
Negative 11 (±9)
aQuantitative immunocytochemical index. bMann-Whitney test.
Table 3 Correlation of Bcl-2 protein expression (anti bcl-2/124, Dako) to cathepsin D CD31, MIBl, P53, P-glycoprotein in 218
breast carcinomas. All antigens were detected by immunohistochemistry on frozen sections, automated procedures (Ventana) and
quantitative analysis (SAMBA image analyser)
p53
p53
Positive
Negative
P-glycoprotein
Positive
Negative
Cathepsin Dpositive
CD 31 positive
MIBl positive (Ki67)
Bcl-2 immunoreaction
Positive Negative
23/51
(45.1%)
142/166
(85.5%)
28/51
(54.9%)
pb < 0.0001
62/169
(37%)
107/169
(63%)
Pb < 0.01
24/166
(14.4%)
Bcl-2 positive surface
(%)
ra = - 0.28
P < 0.0001
ra=-0.34
P< 0.0001
NS
NS
ra = 0.30
P < 0.0001
29/47
(62%)
18/47
(38%)
aPearson's coefficent correlation. bChi-square.
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immunoreactions with anti-p53, anti-cathepsin D, anti-CD-31 and
anti-P-gp are shown in Tables 2 and 3. A significant correlation
was observed between Bcl-2 protein expression and the tumour
tissue contents of ER, PR and pS2 antigens, evaluated by the same
procedure on consecutive frozen sections from the same tissue
blocks (Table 2). An inverse relationship was observed between
Bcl-2 and p53 (P < 0.001) and growth fraction (MIB1/Ki67)
(P < 0.0001) and P-gp (P = 0.0021) expression in tumours (Table
3). In contrast, Bcl-2 was unrelated to CD31 (reflecting stromal
angiogenesis) and to cathepsin D (tumour cell secretion of extra-
cellular matrix protease) (Table 3).
DISCUSSION
In these series, the Bcl-2 protein was detected in 78% of breast
carcinomas by automated and quantitative immunohistochemistry
using frozen samples and Bcl-2/124 MAb. In previous reports,
Bcl-2 protein was detected in 32-75% of cases (Gee et al, 1994;
Johnston et al, 1994; Leek et al, 1994; Nathan et al, 1994;
Silvestrini et al, 1994; Hellemans et al, 1995; Baba et al, 1996).
The results obtained in these different studies cannot be compared
because ofvariations in the methods of detection. However, detec-
tion on frozen samples avoids bias resulting from antigen damage
because of fixatives, uncontrolled fixation duration or uncon-
trolled variations in antigen heating during paraffin embedding.
Also, the results rely upon the quality of the technique (Charpin
et al, 1994b), and ideally automation provides for a better
quality control (Grogan et al, 1993, 1995; Galaktionov et al,
1995), particularly with regard to reproducibility, in addition to the
fact that many tissue samples may be identically probed at the
same time.
Similarly, shortcomings may also result from semiquantitative
analysis ofimmunostaining. Semiquantitative evaluation ofresults
of immunodetection is very convenient, rapidly realized and is an
inexpensive method of analysis. However, its reliability depends
upon observer experience. Although semiquantitative analysis is
sufficient to evaluate negative vs positive reactions, or very weak
vs very strong immunoreactions, it is not sufficiently accurate to
evaluate quantitatively intermediate patterns of staining. This must
be pointed out, particularly when quantitative variations in the
distribution of antigen are correlated with prognostic parameters
such as survival, metastasis and recurrence or various histoprog-
nostic indicators.
Discrepancies in the prognostic significance of Bcl-2 protein
expression in major human carcinomas probably result from this
type of analysis bias. In the present study we evaluated the results
of Bcl-2 protein expression in tissue by computerized processing
ofdigitized microscopic image, using the same hardware and soft-
ware as in previous studies (Charpin et al, 1988 a-c, 1993, 1994a,
b), 1995a, b). The results were obtained more objectively, varia-
tions of staining more accurately evaluated and numerical values
ofparameters were more appropriate to statistical analysis (contin-
uous variables).
We observed that Bcl-2 protein expression was greater in low-
grade than in high-grade tumours when the Bloom grading system
(Bloom, 1957) or a modified system (Le Doussal et al, 1989) was
employed. In these respects our results are not in agreement with
those of others (Hellemans et al, 1995; Nathan et al, 1994).
In contrast, like others (Hellemans et al, 1995), we found no
relationship between Bcl-2 protein expression and tumour size and
the axillary lymph node status.
The prognostic significance of Bcl-2 expression in terms of
relapse-free survival and overall survival has been evaluated in
some recent studies (Nathan et al, 1994; Silvestrini et al, 1994;
Hellemans et al, 1995), using immunohistochemistry of archival
fixed tissue samples, and provided discrepant results. Bcl-2 protein
expression was not significantly related to a better or worse
survival (disease-free survival and overall survival) in the study of
Nathan et al (1994). In contrast, in the study by Hellemans et al
(1995), although no prognostic value was demonstrated for Bcl-2
protein expression on disease-free survival and overall survival in
node-negative breast cancer patients, in node-positive patients
Bcl-2 expression was independently related to shortened survival
(disease-free and overall survival) using multivariate analysis. In
the Silvestrini et al study (1994) Bcl-2 expression in node-negative
patients was related to better 6-year survival, but this predictive
role of Bcl-2 protein expression was mainly dependent on p53
expression. Thus, it appears that the prognostic significance of
Bcl-2 expression in breast carcinomas deserves additional investi-
gations, in larger series, with longer follow-up, and more standard-
ized immunohistochemical assays (work in preparation).
We compared the quantitative evaluation of Bcl-2 expression in
tissue with tumour growth fraction as evaluated by MIB1 MAb.
Previous reports have shown discrepant results, demonstrating
a non-relationship between Ki67-positive immunoreaction and
Bcl-2 protein expression (Gee et al, 1994) or an inverse relation-
ship (Johnston et al, 1994). In our series we also observed
an inverse relationship between growth fraction and Bcl-2 expres-
sion (P < 0.0001).
In contrast, we observed no relationship between Bcl-2 expres-
sion and anti-CD-31 (Charpin et al, 1995b) or anti-cathepsin D
(Charpin et al, 1993; Maudelonde et al, 1993) positive immuno-
reactions, suggesting that Bcl-2 involvement in the apoptotic
process is independent of angiogenesis and protease synthesis,
acting on extracellular matrix digestion. These results also suggest
that Bcl-2 is independent of mechanisms oftumour progression.
It has been shown that the bcl-2 gene can inhibit apoptosis trig-
gered by the wild-type p53 gene (Wang et al, 1993). In-contrast,
the mutantp53 gene can inhibit apoptosis (Lotem, 1993) although
it does not seem to have the same large protective range as bcl-2
(Sachs, 1993). An inverse correlation between the expression of
Bcl-2 protein and mutant p53 was observed in the MCF 7 breast
cancer cell line (Haldar et al, 1994) and in tissue sections of breast
carcinomas (Baba et al, 1996; Silvestrini et al, 1994), as in our
study, suggesting that mutant p53 could substitute for bcl-2
function in breast cancer cells and that it could also down-regulate
Bcl-2 expression (Haldar et al, 1994).
We observed an inverse relationship between Bcl-2 and P-gp
expression that is related to multidrug resistance. These results are
also paradoxical as Bcl-2 protein has been shown to be involved in
chemoresistance (Alnemri et al, 1992; Miyashita, 1992; 1993;
Fisher et al, 1993).
Immunostaining of steroid hormone receptors has been shown
to be strongly associated with that of Bcl-2 protein (Gee et al,
1994; Johnston et al, 1994; Nathan et al, 1994; Silvestrini et al,
1994; Hellemans et al, 1995; Baba et al, 1996), suggesting that this
protein is under oestrogen regulation via oestrogen receptors (Gee
et al, 1994). In this respect, the increased expression of Bcl-2
protein in ER-positive tumours of patients treated by tamoxifen
shows that Bcl-2 protein expression can be modulated by therapy
with anti-oestrogens (Johnston et al, 1994). We observed that
Bcl-2 expression was significantly associated with ER-positive
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detection in tumours (P< 0.001) and with ER+/PR+/pS2+ (P <
0.001). These results suggest that Bcl-2 protein is probably
involved in the response to endocrine therapy. This is unexpected,
as mentioned above, as Bcl-2 is thought to prevent programmed
cell death and should counteract the tumour-inhibitory effects of
endocrine therapy. Indeed, patients whose tumours have strong
Bcl-2 immunostaining appear to derive the greatest benefit from
endocrine therapy (Gee et al, 1994).
The role of bcl-2 and the significance of Bcl-2 protein in breast
carcinomas remains to be elucidated, in particular it remains to be
seen whether Bcl-2 expression is involved directly in the patho-
genesis ofbreast carcinomas or, alternatively, whether it is induced
secondarily by other genomic changes in tumour cells responsible
for modulation of Bcl-2 protein expression. Our results suggest
that Bcl-2 protein is related to tumour cell differentiation (grade
and hormone receptors), independent oftumour progression (node
status, tumour size, stromal angiogenesis and tumour proteasic
activity). The potential role ofBcl-2 expression in patient response
to endocrine therapy orchemotherapy emphasizes the clinical rele-
vance ofBcl-2 protein immunodetection in tumours. However, the
use of Bcl-2 immunohistochemical assays in the monitoring of
patient therapy requires optimal technical conditions of detection
that can be obtained in automated and quantitative (image
analysis) immunohistochemical procedures using frozen tumour
samples and well-documented monoclonal antibodies.
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